Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential

1 day ago 3

Maham Fatima

Mon, December 22, 2025 astatine 7:42 AM CST 2 min read

DexCom Inc. (NASDAQ:DXCM) is 1 of the best maturation stocks to bargain successful 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a terms people of $75, which was up from $63. The steadfast noted that the institution is overcoming caller operational hurdles portion its banal remains astatine humanities lows. Morgan Stanley expects the afloat scope of this betterment to beryllium disposable by aboriginal adjacent twelvemonth and believes that investors are presently undervaluing the G7 rollout’s borderline potential.

Earlier connected November 25, Evercore ISI initiated sum of DexCom with an In Line standing and $68 terms target. While acknowledging that DexCom operates successful a ample and vastly underpenetrated diabetes market, the steadfast maintained an In Line standing owed to expectations of continued headwinds. Evercore ISI believes that a operation of merchandise prime concerns, manufacturing challenges, and intensifying competitory threats volition apt hinder DexCom’s quality to seizure further marketplace stock done 2026.

Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential

In different news, connected November 19, DexCom announced that the FDA cleared Dexcom Smart Basal, making it the archetypal and lone CGM-integrated basal insulin dosing optimizer for adults aged 18 and older with Type 2 diabetes. Specifically designed for patients utilizing glargine U-100 long-acting insulin, this caller instrumentality simplifies the often hard process of insulin initiation and management. The strategy uses information from the Dexcom G7 15 Day sensor and logged insulin doses to make personalized regular recommendations. The exertion is intended to region communal barriers to insulin therapy, specified arsenic the fearfulness of hypoglycemia and the months of proceedings and mistake typically required to find an effectual dose.

DexCom Inc. (NASDAQ:DXCM) is simply a aesculapian instrumentality institution that designs, develops, and commercializes continuous glucose monitoring/CGM systems successful the US and internationally.

While we admit the imaginable of DXCM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.